NCT04093076 is a Phase 1 clinical trial of INO-4500 in Lassa Fever, sponsored by Inovio Pharmaceuticals.

Who is sponsoring NCT04093076?

NCT04093076 is sponsored by Inovio Pharmaceuticals.

What drugs are being tested in NCT04093076?

Interventions in NCT04093076: INO-4500, CELLECTRA™ 2000, Placebo.

What condition does NCT04093076 study?

NCT04093076 studies Lassa Fever.

Is NCT04093076 still recruiting?

NCT04093076 is currently completed. Last updated 21 November 2022.

Last reviewed 2022-11-21 · How we verify

NCT04093076

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

Completed Phase 1 Last updated 21 November 2022

What this trial tests

Phase 1 trial testing INO-4500 in Lassa Fever in 220 participants. Completed in 14 October 2022.

Timeline

27 January 2021

Primary endpoint
14 October 2022

14 October 2022

Quick facts

Lead sponsor	Inovio Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	220
Start date	27 January 2021
Primary completion	14 October 2022
Estimated completion	14 October 2022
Sites	1 location across Ghana

Drugs / interventions tested

INO-4500 — full drug profile →
CELLECTRA™ 2000
Placebo

Conditions studied

Lassa Fever — all drugs for Lassa Fever →

Sponsor

Inovio Pharmaceuticals — full company profile →

Who can join

Adults 18 to 50, any sex, with Lassa Fever. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, blinded, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA™ 2000 device in healthy volunteers in Ghana.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Lassa fever vaccine candidates: A scoping review of vaccine clinical trials.
Sulis G, Peebles A, Basta NE. · · 2023 · cited 31× · PMID 37095630 · DOI 10.1111/tmi.13876
Distinct Molecular Mechanisms of Host Immune Response Modulation by Arenavirus NP and Z Proteins.
Stott RJ, Strecker T, Foster TL. · · 2020 · cited 15× · PMID 32708250 · DOI 10.3390/v12070784
Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults.
Koram KA, Walker KA, Orizu B, Marrero I, et al · · 2025 · cited 1× · PMID 41208990 · DOI 10.3389/fimmu.2025.1658549
Efficacy, safety, and immunogenicity of Lassa fever vaccines: A living systematic review and landscape analysis of vaccine candidates.
Bardach A, Berrueta M, Ciapponi A, Sambade JM, et al · · 2025 · PMID 41406099 · DOI 10.1371/journal.pone.0338128

Verify or expand the search:

Other trials of INO-4500

Trials testing the same drug.

NCT03805984 — Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Lassa Fever

Currently open trials in the same condition.

NCT03655561 — Lassa Fever Clinical Course and Prognostic Factors in Nigeria · active not recruiting

Other Inovio Pharmaceuticals trials

Trials by the same sponsor.

NCT04588428 — Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers · Phase 2 · completed
NCT04642638 — Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure · Phase 2, PHASE3 · terminated
NCT04398433 — INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomat · Phase 1, PHASE2 · completed
NCT04336410 — Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers · Phase 1 · completed
NCT03805984 — Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04093076 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inovio Pharmaceuticals
Last refreshed: 21 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04093076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing